Literature DB >> 7543878

Cytokines as adjuvants for vaccines: antigen-specific responses differ from polyclonal responses.

C E Taylor1.   

Abstract

The use of cytokines in the administration of vaccines has a unique value in obtaining the appropriate immune response and in ensuring a protective outcome. Earlier studies indicating that cytokines can influence the generation of a particular antibody isotype may represent an oversimplification of a more complex problem. Several studies discussed in this review show that the effect of a given cytokine on the immune response depends on whether one examines the antigen-specific response or the polyclonal response (i.e., total serum immunoglobulins). Further, a balanced regulation of immune responsiveness is important in maintaining homeostasis of the immune system. Consequently, for any vaccine that uses cytokines to boost the response, due consideration must be given to these important variables.

Mesh:

Substances:

Year:  1995        PMID: 7543878      PMCID: PMC173446          DOI: 10.1128/iai.63.9.3241-3244.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  The stimulation of T cells with anti-CD2 monoclonal antibodies facilitates the induction of polyclonal B-cell responses but does not enhance the activation of antigen-specific B cells.

Authors:  R Trifiletti; B Hyman; M LaVia; W Knapp; G Virella
Journal:  Scand J Immunol       Date:  1990-01       Impact factor: 3.487

2.  Molecular characterization of germ-line immunoglobulin A transcripts produced during transforming growth factor type beta-induced isotype switching.

Authors:  D A Lebman; D Y Nomura; R L Coffman; F D Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  Antibody production in vitamin A-depleted rats is impaired after immunization with bacterial polysaccharide or protein antigens.

Authors:  A M Pasatiempo; M Kinoshita; C E Taylor; A C Ross
Journal:  FASEB J       Date:  1990-05       Impact factor: 5.191

4.  Increased activation of antigen-primed or memory B cells by bacterial lipopolysaccharide.

Authors:  M B Fauntleroy; J A Rudbach; B Prescott; P J Baker
Journal:  Cell Immunol       Date:  1987-07       Impact factor: 4.868

5.  Inhibition of T cell-dependent antibody production by D-penicillamine. Different requirements for Cu2+ in suppression of polyclonal and antigen-specific B cell responses.

Authors:  J Petersen
Journal:  Allergy       Date:  1987-01       Impact factor: 13.146

6.  Effects of interferon gamma on the antibody response to Pseudomonas aeruginosa lipopolysaccharide in mice.

Authors:  C E Taylor; P J Baker; T Hraba; P Stashak; M B Fauntleroy
Journal:  Immunobiology       Date:  1994-12       Impact factor: 3.144

7.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

8.  The polyclonal and antigen-specific IgE and IgG subclass response of mice injected with ovalbumin in alum or complete Freund's adjuvant.

Authors:  L Beck; H L Spiegelberg
Journal:  Cell Immunol       Date:  1989-10-01       Impact factor: 4.868

9.  IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses.

Authors:  F D Finkelman; I M Katona; T R Mosmann; R L Coffman
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

10.  IgG2a restriction of murine antibodies elicited by viral infections.

Authors:  J P Coutelier; J T van der Logt; F W Heessen; G Warnier; J Van Snick
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

View more
  14 in total

1.  rIL-22 as an adjuvant enhances the immunogenicity of rGroEL in mice and its protective efficacy against S. Typhi and S. Typhimurium.

Authors:  Gurpreet Kaur; Chitradevi STS; Charu Nimker; Anju Bansal
Journal:  Cell Mol Immunol       Date:  2014-05-26       Impact factor: 11.530

2.  The method of noncovalent in vitro binding of target proteins to virus-like nanoparticles formed by core antigen of hepatitis B virus.

Authors:  E A Blokhina; V V Kupriyanov; N V Ravin; K G Skryabin
Journal:  Dokl Biochem Biophys       Date:  2013-03-13       Impact factor: 0.788

3.  Interleukin-4 causes delayed virus clearance in influenza virus-infected mice.

Authors:  T M Moran; H Isobe; A Fernandez-Sesma; J L Schulman
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

Review 4.  Vaccination strategies for mucosal immune responses.

Authors:  P L Ogra; H Faden; R C Welliver
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  Immune responses to Plasmodium falciparum-merozoite surface protein 1 (MSP1) antigen, II. Induction of parasite-specific immunoglobulin G in unsensitized human B cells after in vitro T-cell priming with MSP119.

Authors:  O Garraud; A Diouf; I Holm; R Perraut; S Longacre
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

6.  Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines.

Authors:  C M Ausiello; F Urbani; A la Sala; R Lande; A Cassone
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

7.  Immunity against Yersinia enterocolitica by vaccination with Yersinia HSP60 immunostimulating complexes or Yersinia HSP60 plus interleukin-12.

Authors:  A Noll
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

Review 8.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

9.  Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund's adjuvant, and monophosphoryl lipid A.

Authors:  Juliana Vitoriano-Souza; Nádia das Dores Moreira; Andréa Teixeira-Carvalho; Cláudia Martins Carneiro; Fernando Augusto Mathias Siqueira; Paula Melo de Abreu Vieira; Rodolfo Cordeiro Giunchetti; Sandra Aparecida de Lima Moura; Ricardo Toshio Fujiwara; Maria Norma Melo; Alexandre Barbosa Reis
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

10.  Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model.

Authors:  H Kusnierczyk; E Pajtasz-Piasecka; C Radzikowski
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.